An unsuspected property of natriuretic peptides: Promotion of calcium-dependent catecholamine release via protein kinase g-mediated phosphodiesterase type 3 inhibition
Cyclic GMP-Dependent Protein Kinases
Natriuretic Peptide, Brain
Phosphodiesterase 3 Inhibitors
Our results show that natriuretic peptides, at concentrations likely to be reached at cardiac sympathetic nerve endings in advanced congestive heart failure, promote norepinephrine release via a protein kinase G-induced inhibition of phosphodiesterase type 3-mediated cAMP hydrolysis. We propose that this proadrenergic action may counteract the beneficial cardiac and hemodynamic effects of natriuretic peptides and thus explain the ineffectiveness of nesiritide as a cardiac failure medication.